{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T07:29:06Z","timestamp":1774510146932,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/wnf.0b013e318259eac8","type":"journal-article","created":{"date-parts":[[2012,6,2]],"date-time":"2012-06-02T07:39:02Z","timestamp":1338622742000},"page":"165-173","source":"Crossref","is-referenced-by-count":37,"title":["A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Pharmacokinetics, Efficacy, and Safety of Gabapentin Enacarbil in Subjects With Restless Legs Syndrome"],"prefix":"10.1097","volume":"35","author":[{"given":"Ritu","family":"Lal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Zomorodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harisha","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Tovera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Bonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Liesse","family":"Lassauzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Cundy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":". Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2006.11.004","article-title":"Current guidelines and standards of practice for restless legs syndrome.","volume":"120","author":"Hening","year":"2007","journal-title":"Am J Med"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4065\/79.7.916","article-title":". An algorithm for the management of restless legs syndrome.","volume":"79","author":"Silber","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":". Randomized, double-blind, placebo-controlled trial of XP13512GSK1838262 in patients with RLS.","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/sleep\/32.2.159","article-title":". A randomized, double-blind, placebo-controlled, crossover study of XP13512GSK1838262 in the treatment of patients with primary restless legs syndrome.","volume":"32","author":"Kushida","year":"2009","journal-title":"Sleep"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":". XP13512 ()-1-((alpha-isobutanoyloxyethoxy)carbonyl aminomethyl)-1-cyclohexane acetic acid, a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":". XP13512 ()-1-((alpha-isobutanoyloxyethoxy)carbonyl aminomethyl)-1-cyclohexane acetic acid, a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0091270008322909","article-title":". Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.","volume":"48","author":"Cundy","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1023\/A:1018951214146","article-title":". A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma.","volume":"10","author":"Stewart","year":"1993","journal-title":"Pharm Res"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00020-5","article-title":". Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.","volume":"31","author":"Gidal","year":"1998","journal-title":"Epilepsy Res"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-1211(00)00117-0","article-title":". Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability.","volume":"40","author":"Gidal","year":"2000","journal-title":"Epilepsy Res"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","article-title":". Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.","volume":"4","author":"Walters","year":"2003","journal-title":"Sleep Med"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1389-9457(03)00009-1","article-title":"Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures.","volume":"4","author":"Hening","year":"2003","journal-title":"Sleep Med"},{"key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1037\/1040-3590.7.1.80","article-title":"Short form of the Profile of Mood States: psychometric information.","volume":"7","author":"Curran","year":"1995","journal-title":"Psychology Assessment"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":". The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr Res"},{"key":"R20-3-20210203","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1176\/appi.ajp.163.3.426","article-title":". The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.","volume":"163","author":"Keefe","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R21-3-20210203","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-1781(88)90076-5","article-title":". The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families.","volume":"26","author":"Cornblatt","year":"1988","journal-title":"Psychiatry Res"},{"key":"R22-3-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(05)70139-3","article-title":"The restless legs syndrome.","volume":"4","author":"Trenkwalder","year":"2005","journal-title":"Lancet Neurol"},{"key":"R23-3-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale.","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"R24-3-20210203","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/sleep\/15.4.376","article-title":"Reliability and factor analysis of the Epworth Sleepiness Scale.","volume":"15","author":"Johns","year":"1992","journal-title":"Sleep"},{"key":"R25-3-20210203","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/WNF.0b013e3181b3ab16","article-title":". Gabapentin enacarbil in restless legs syndrome: a phase 2b, two-week, randomized, double-blind, placebo-controlled trial.","volume":"32","author":"Walters","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"R26-3-20210203","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":". Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"R27-3-20210203","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2125.2010.03616.x","article-title":". Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.","volume":"69","author":"Lal","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R28-3-20210203","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.clinthera.2009.07.026","article-title":". Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.","volume":"31","author":"Lal","year":"2009","journal-title":"Clin Ther"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-201207000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:52:49Z","timestamp":1618278769000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201207000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318259eac8","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}